News

  • 5 January 2012

    Ista begins Beposone nasal spray study

    Ista Pharmaceuticals' Beposone nasal spray has entered into a Phase II clinical study in conjugation with bepotastine besilate and a steroid for the treatment of the symptoms associated with seasonal...

  • 5 January 2012

    Baxter doses first patient in BAX 855 drug study

    Baxter International has begun dosing the first patients in a Phase I clinical trial of investigational candidate BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII)...

  • 4 January 2012

    Achillion HCV drug receives FDA fast track status

    The US Food and Drug Administration (FDA) has granted fast track designation to Achillion Pharmaceuticals' ACH-1625 drug, which is being evaluated in a Phase II clinical trial as a treatment...

  • 2 January 2012

    Pfizer pneumonia vaccine receives FDA clearance

    The US Food and Drug Administration (FDA) has approved the extended use of Pfizer's pneumococcal conjugate vaccine- Prevnar 13 as a single-dose treatment for pneumonia in adults.

  • 22 December 2011

    Xoma commences Gevokizumab Phase II study

    Xoma has initiated patient dosing in its Phase II proof-of-concept study, designed to investigate the efficacy and safety of Gevokizumab (XOMA 052), an inhibitor of interleukin-1 beta, used to treat...

Go Top